At RFA, we are committed to advancing global health and research through the development of precise, high-quality monoclonal antibodies (mAbs). Our work supports scientists, medical researchers, and diagnostic developers around the world by providing dependable, application ready antibodies tailored to critical challenges in medicine and life sciences.

About Us

Focused on Research, Driven by Discovery

At RFA, we specialize in researching and discovering monoclonal antibodies that support advances in science and medicine.

What Is an Antibody?

Nature’s Most Precise Binding Molecule

Antibodies are Y-shaped proteins naturally produced by the immune system to identify and neutralize foreign substances, such as bacteria, viruses, and toxins. They recognize specific molecular targets known as antigens and bind to them with high precision.

In scientific research, antibodies are essential for:

Detecting proteins in cells and tissues
Measuring biomarkers in biological fluids
Studying cellular mechanisms and pathways
Supporting diagnostics and drug development

What Are Monoclonal Antibodies?

Single-Target, High-Specificity Molecules

Monoclonal antibodies (mAbs) are identical copies of a single immune cell’s antibody, meaning they bind to one unique epitope on a target molecule. This level of specificity makes them ideal for use in both research and clinical development.

At RFA, we develop monoclonal antibodies using:

Hybridoma technology (mouse, rabbit)
Recombinant expression systems
Antibody engineering and optimization
Epitope selection and validation

Our mAbs are validated for:

Western blot
Immunohistochemistry (IHC)
Flow cytometry
ELISA and other immunoassays

Learn more

Our Focus

Specialized Research in Antibody Development

RFA Biotech focuses on three core areas:

Target Discovery & R&D

Identification of novel and disease-relevant antigens
Generation of hybridomas and recombinant clones
In vitro and in vivo testing models

Antibody Engineering & Validation

Humanization, fragment generation (Fab, scFv)
Isotyping and sequence confirmation
ELISA, WB, IHC, IF, and FACS application validation

Scientific Support & Collaboration

Collaborative research models
Antibody optimization for specific applications
Flexible batch sizes for early-stage studies

Monoclonal Antibodies in Parkinson’s Disease Research

Precision Tools for Understanding Neurodegeneration

Parkinson’s disease (PD) is a complex neurodegenerative condition that affects movement, cognition, and behavior. It is closely associated with the accumulation of misfolded proteins such as alpha-synuclein, as well as disruptions in mitochondrial function, inflammation, and synaptic integrity.

At RFA, we support Parkinson’s research by developing monoclonal antibodies that target:

Alpha-synuclein (total and phospho-Ser129 forms)
Tau proteins (phospho-Tau, total Tau)
Parkin, DJ-1, and LRRK2
Neuroinflammation markers (GFAP, Iba1, IL-1β)

Why Choose RFA?

Trusted by Scientists for Quality and Reproducibility

Deep Scientific Expertise
Our team brings years of experience in antibody development, protein analysis, and assay validation.
Stringent Quality Standards
Every antibody is tested for sensitivity, specificity, and consistency across multiple applications.
Flexible Solutions
From catalog antibodies to custom development services, we support research at every stage.
Reliable Performance
Batch-to-batch consistency, detailed technical data, and strong application support are standard with every product.

Welcome to RFA

Advancing Antibody Science for a Healthier Future